Overview

Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Status:
Completed
Trial end date:
2016-05-23
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the efficacy and safety of TAS-102 versus placebo in patients with refractory metastatic colorectal cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Taiho Oncology, Inc.
Treatments:
Trifluridine